Sera Prognostics Names Dr. Tiffany Inglis Chief Medical Officer

SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company^® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to doctors and patients, today announced the appointment of Tiffany Inglis, MD, FACOG, as Chief Medical Officer. With extensive clinical leadership expertise, Dr. Inglis will lead Sera's clinical operations to establish the company as a leader in women's health diagnostics to improve the health of pregnant women and newborns.

Dr. Inglis joins Sera following years of clinical leadership positions at Elevance Health and Carelon Health where she focused on member facing programs including women's and children's health, driving initiatives that improved access to quality care while demonstrating meaningful cost-savings. Her expertise in clinical operations will bolster Sera's commercial strategy as the company looks to position its data to drive coverage, support updates to clinical practice guidelines and help ensure the PreTRM® Test is standard of care to benefit babies and families.

"As an OBGYN, Dr. Inglis understands the importance of delivering real-time, actionable information to patients that can achieve healthier outcomes for both mom and baby," said Zhenya Lindgardt, CEO of Sera Prognostics. "The intersection of her clinical expertise and her more recent tenure as Chief Medical Officer and Medical Director across major payer networks makes her the perfect fit for Sera during a pivotal time, as we prepare for publication of the PRIME study and launch pilots with state Medicaid programs with our breakthrough PreTRM Test."

Dr. Inglis received a medical degree from the Medical College of Ohio in 2002 and completed an Obstetrics and Gynecology residency at Riverside Methodist Hospital in Columbus, Ohio in 2006. She spent over a decade as a practicing OBGYN throughout Ohio and has contributed her expertise to numerous scientific articles and journals throughout her career on topics related to cost-effective solutions to improve maternal and neonatal outcomes.

"I've dedicated my career to improving outcomes for mothers and babies, and I'm thrilled to join Sera to continue this work," said Dr. Inglis. "Sera has an incredible opportunity to transform the maternal and neonatal care landscape to be more proactive, personalized and accessible for women to ultimately make the best decisions about their health. I look forward to collaborating on the organization's leading innovation to drive greater awareness around pre-term birth to deliver meaningful clinical outcomes for women and babies."

About Sera Prognostics, Inc.
Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM ®Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.

About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2024 March of Dimes Report Card shows that, for the last six consecutive years, more than one in ten infants is born prematurely in the United States. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately $25 billion for 2016.

About the PreTRM ^® Test
The PreTRM Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM Test is ordered by a medical professional.

Sera, Sera Prognostics, the Sera Prognostics logo, The Pregnancy Company, and PreTRM are trademarks or registered trademarks of Sera Prognostics, Inc. in the United States and/or other countries.

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to establishing the Company as a leader in women's health diagnostics; driving coverage, supporting updates to clinical practice guidelines and ensuring the PreTRM® Test is standard of care; publication of the PRIME study; launching pilots with state Medicaid programs; transforming the maternal and neonatal care landscape to be more proactive, personalized and accessible for women; and the Company's strategic directives under the caption "About Sera Prognostics, Inc." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading "Risk Factors" contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

Contact
Investor Contact
Jennifer Zibuda
Head of Investor Relations
[email protected]
(801) 396-8043

SOURCE Sera Prognostics, Inc.